These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29724466)

  • 1. Voice Quality and Orofacial Strength as Outcome of Levodopa Effectiveness in Patients with Early Idiopathic Parkinson Disease: A Preliminary Report.
    Lechien JR; Blecic S; Ghosez Y; Huet K; Harmegnies B; Saussez S
    J Voice; 2019 Sep; 33(5):716-720. PubMed ID: 29724466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orofacial Strength and Voice Quality as Outcome of Levodopa Challenge Test in Parkinson Disease.
    Lechien JR; Delsaut B; Abderrakib A; Huet K; Delvaux V; Piccaluga M; Khalife M; Harmegnies B; Saussez S; Blecic S
    Laryngoscope; 2020 Dec; 130(12):E896-E903. PubMed ID: 32239775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease.
    Gallena S; Smith PJ; Zeffiro T; Ludlow CL
    J Speech Lang Hear Res; 2001 Dec; 44(6):1284-99. PubMed ID: 11776365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Levodopa + Carbidopa on the Laryngeal Electromyographic Pattern in Parkinson Disease.
    Noffs G; de Campos Duprat A; Zarzur AP; Cury RG; Cataldo BO; Fonoff E
    J Voice; 2017 May; 31(3):383.e19-383.e23. PubMed ID: 27839704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voice quality severity and responsiveness to levodopa in Parkinson's disease.
    Cushnie-Sparrow D; Adams S; Abeyesekera A; Pieterman M; Gilmore G; Jog M
    J Commun Disord; 2018; 76():1-10. PubMed ID: 30053648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Speech and voice disorders in Parkinson's disease].
    Martnez-Sánchez F
    Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of levodopa on vocal function in Parkinson's disease.
    Sanabria J; Ruiz PG; Gutierrez R; Marquez F; Escobar P; Gentil M; Cenjor C
    Clin Neuropharmacol; 2001; 24(2):99-102. PubMed ID: 11307045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary study of Novafon local vibration voice therapy for dysphonia treatment.
    Barsties V Latoszek B
    Logoped Phoniatr Vocol; 2020 Apr; 45(1):1-9. PubMed ID: 29583016
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of levodopa treatment in the voice pattern of Parkinson's disease patients: a systematic review and meta-analysis.
    Pinho P; Monteiro L; Soares MFP; Tourinho L; Melo A; Nóbrega AC
    Codas; 2018 Oct; 30(5):e20170200. PubMed ID: 30304100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Laryngopharyngeal Reflux on Subjective, Aerodynamic, and Acoustic Voice Assessments of Responder and Nonresponder Patients.
    Lechien JR; Finck C; Huet K; Khalife M; Fourneau AF; Delvaux V; Piccaluga M; Harmegnies B; Saussez S
    J Voice; 2019 Nov; 33(6):929-939. PubMed ID: 30057272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of Life and Voice Changes After a Single Injection in Patients With ADSD Over Time.
    Faham M; Torabinezhad F; Murry T; Dabirmoghaddam P; Abolghasemi J; Kamali M; Asgari M
    J Voice; 2019 Sep; 33(5):721-727. PubMed ID: 29884509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A panel of jitter/shimmer may identify functional dysphonia at risk of failure after speech therapy.
    Lovato A; Bonora C; Genovese E; Amato C; Maiolino L; de Filippis C
    Am J Otolaryngol; 2020; 41(4):102455. PubMed ID: 32475619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Electrostimulation Effect in Women With Vocal Nodules.
    Santos JK; Silvério KC; Diniz Oliveira NF; Gama AC
    J Voice; 2016 Nov; 30(6):769.e1-769.e7. PubMed ID: 26822388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidimensional Assessment of the Effectiveness of Group Voice Therapy.
    Cantarella G; Torretta S; Ferruta S; Ciabatta A; Manfredi C; Pignataro L; Dejonckere P
    J Voice; 2017 Nov; 31(6):714-721. PubMed ID: 28259606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems.
    Plowman-Prine EK; Okun MS; Sapienza CM; Shrivastav R; Fernandez HH; Foote KD; Ellis C; Rodriguez AD; Burkhead LM; Rosenbek JC
    NeuroRehabilitation; 2009; 24(2):131-44. PubMed ID: 19339752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
    Pawlukowska W; Gołąb-Janowska M; Safranow K; Rotter I; Amernik K; Honczarenko K; Nowacki P
    Neurol Neurochir Pol; 2015; 49(5):302-6. PubMed ID: 26377981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease.
    Goberman AM
    Med Sci Monit; 2005 Mar; 11(3):CR109-16. PubMed ID: 15735562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of VHI-30 to Acoustic Measurements Across Three Common Voice Disorders.
    Dehqan A; Yadegari F; Scherer RC; Dabirmoghadam P
    J Voice; 2017 Jan; 31(1):34-40. PubMed ID: 27085912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acoustic analyses of thyroidectomy-related changes in vowel phonation.
    Solomon NP; Awan SN; Helou LB; Stojadinovic A
    J Voice; 2012 Nov; 26(6):711-20. PubMed ID: 23177742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of three semi-occluded vocal tract therapy programmes on the phonation of patients with dysphonia: lip trill, water-resistance therapy and straw phonation.
    Meerschman I; Van Lierde K; Ketels J; Coppieters C; Claeys S; D'haeseleer E
    Int J Lang Commun Disord; 2019 Jan; 54(1):50-61. PubMed ID: 30408272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.